Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multip... (ong patientsin the treatment group recei...)

HOME >> MEDICINE >> TECHNOLOGY

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

Date:9/2/2008

ong patients in the treatment group receiving the combination of bortezomib and mapatumumab at 20 mg/kg, vs. no complete responses in the group receiving bortezomib alone.

-- Clinical responses were observed in 51.4% (18/35) of patients in the treatment group receiving bortezomib alone (0 complete and 18 partial). The response rate observed for bortezomib in the current study compares with a response rate identified in the FDA-approved bortezomib label of approximately 38%.

-- Clinical responses were observed in 50.0% (18/36) of patients in the treatment group receiving the combination of bortezomib and mapatumumab at 20 mg/kg (3 complete and 15 partial).

-- Clinical responses were observed in 30.3% (10/33) of patients in the treatment group receiving the combination of bortezomib and mapatumumab at 10 mg/kg (0 complete and 10 partial).

-- Stable disease was observed in approximately a third of the patients on study and was comparable across all treatment groups.

The multiple myeloma study is ongoing, and 58 patients in this study have not yet experienced disease progression and continue to be treated and/or followed.

About the HGS-ETR1 Proof-of-Concept Trials

The HGS-ETR1 proof-of-concept phase currently includes three randomized trials to evaluate its potential in combination with chemotherapy for the treatment of specific cancers:

-- Patients in the multiple myeloma trial will continue on treatment until the progression of disease, and HGS expects to have final data available from this study in 2009, including data on the important secondary endpoint of progression-free survival.

-- In August 2008, the Company completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (10 mg/kg or 30 mg/kg) in combination with paclitaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC); initial data from the study are anticipated
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials

Post Your Comments:

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multip...(ong patientsin the treatment group recei...),Health